| A Prefilled Insulin Pen with a Novel Injection Mechanism and a Lower Injection Force than Other Prefilled Insulin Pens. | |
| | |
MedLine Citation:
|
PMID: 21864019 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Abstract Background: FlexTouch(®) (Novo Nordisk A/S, Bagsvaerd, Denmark) is a new prefilled insulin pen for people with diabetes, with a novel injection mechanism and no push-button extension at any dose setting. This study compared the injection force of FlexTouch with that of SoloStar(®) (Sanofi-Aventis, Paris, France) and KwikPen(®) (Eli Lilly & Co., Indianapolis, IN). Methods: Injection force was measured with the manufacturers' recommended needle attached to each pen (NovoFine(®) [Novo Nordisk] 32-gauge tip extra thin wall 6 mm needle for FlexTouch and BD [Franklin Lakes, NJ] MicroFine™ 31-gauge 5 mm needle for SoloStar and KwikPen) during injection of the maximum dose (60 IU for KwikPen and 80 IU for FlexTouch and SoloStar). Injection was performed at three different constant push-button speeds. Results: FlexTouch had a significantly (P<0.0001) lower injection force than SoloStar and KwikPen at all injection speeds. The mean±SD injection force of FlexTouch was 5.1±0.5 N. At 4, 6, and 8 mm/s push-button speeds, the injection force of SoloStar was 13.5±2.1, 19.1±1.9, and 26.9±2.4 N, respectively, and the injection force of KwikPen was 14.5±1.9, 20.9±1.4, and 28.2±1.4 N, respectively. Conclusions: The injection mechanism of FlexTouch means that insulin injection is driven by a torque spring and not the thumb pressure of the user. This results in a 62-82% lower injection force with FlexTouch than other prefilled insulin pens. |
| | |
Authors:
|
Hans Hemmingsen; Marcus Niemeyer; Marianne Rye Hansen; Ditlef Bucher; Niels Bjerrum Thomsen |
Related Documents
:
|
19720789 - Impact of 9 days of bed rest on hepatic and peripheral insulin action, insulin secretio... 17430239 - Insulin resistance and alzheimer's disease pathogenesis: potential mechanisms and impli... 21573089 - Off-label use of intravitreal triamcinolone acetonide for diabetic macular edema in a p... 7573099 - Clinical implications of insulin resistance syndromes. 15196139 - Update on diabetes mellitus and related oral diseases. 15163119 - Serum magnesium levels in non-diabetic offspring of patients with type 2 diabetes melli... 12808889 - Somatokine. insmed. 21988529 - The choice of thujone as drug for diabetes. 3283119 - Intracellular insulin-receptor dissociation and segregation in a rat fibroblast cell li... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-8-24 |
Journal Detail:
|
Title: Diabetes technology & therapeutics Volume: - ISSN: 1557-8593 ISO Abbreviation: - Publication Date: 2011 Aug |
Date Detail:
|
Created Date: 2011-8-25 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100889084 Medline TA: Diabetes Technol Ther Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
1 Novo Nordisk A/S , Hillerød, Denmark . |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A Multiple Local Models Approach to Accuracy Improvement in Continuous Glucose Monitoring.
Next Document: Chlamydia and chronic arthritis.